Stocktoria
RadNet, Inc. RDNT
RadNet, Inc. (RDNT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $2.0B at a -0.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-20 | Barclays | Overweight (main) |
| 2026-04-21 | Barclays | Overweight (main) |
| 2026-01-09 | Keybanc | Overweight (init) |
| 2025-12-01 | B. Riley Securities | Buy (main) |
| 2025-11-13 | Barclays | Overweight (main) |
| 2025-11-12 | Truist Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.118 |
| Retained earnings / assets | -0.025 |
| EBIT / assets | 0.016 |
| Equity / liabilities | 0.564 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RDNT | RadNet, Inc. | 3/9 | 1.4 | — | +11.5% |
| NTRA | Natera, Inc. | 3/9 | 0.87 | — | +35.9% |
| FTRE | Fortrea Holdings Inc. | 3/9 | -3.58 | — | +1% |
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
About RadNet, Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
FAQ
Is RDNT financially healthy?
RadNet, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does RDNT pay a dividend?
No, RadNet, Inc. does not currently pay a dividend.
How profitable is RDNT?
In FY2025, RadNet, Inc. had a net margin of -0.9% and a return on equity of -1.4%.
Is RDNT overvalued or undervalued?
RadNet, Inc. trades at about 1923.7× trailing earnings — above its 10-year norm (10-year range 20.7×–1636.8×, median 77.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for RDNT?
The average Wall-Street price target for RadNet, Inc. is $89.75, about 16.6% above the recent price, from 8 analysts (consensus: strong buy).
Is RDNT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RadNet, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.